Summary
16.24 -0.03(-0.15%)06/28/2024
Teva- Pharmaceutical Industries Ltd. (TEVA)
Teva- Pharmaceutical Industries Ltd. (TEVA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.09 | -4.50 | -3.16 | 14.98 | 55.06 | 116.18 | 75.89 | 2,575.04 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 16.24 | |
| Open | 16.38 | |
| High | 16.47 | |
| Low | 16.16 | |
| Volume | 6,842,781 | |
| Change | -0.02 | |
| Change % | -0.09 | |
| Avg Volume (20 Days) | 7,237,441 | |
| Volume/Avg Volume (20 Days) Ratio | 0.95 | |
| 52 Week Range | 7.42 - 17.69 | |
| Price vs 52 Week High | -8.22% | |
| Price vs 52 Week Low | 118.80% | |
| Range | -0.89 | |
| Gap Up/Down | -0.18 | |
Fundamentals | ||
| Market Capitalization (Mln) | 18,405 | |
| EBIDTA | 4,333,000,192 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 1.8426 | |
| WallStreet Target Price | 15.50 | |
| Book Value | 6.6950 | |
| Earnings Per Share | -0.5000 | |
| EPS Estimate Current Quarter | 0.7700 | |
| EPS Estimate Next Quarter | 0.5000 | |
| EPS Estimate Current Year | 2.4100 | |
| EPS Estimate Next Year | 2.6400 | |
| Diluted EPS (TTM) | -0.5000 | |
| Revenues | ||
| Profit Marging | -0.0353 | |
| Operating Marging (TTM) | 0.2805 | |
| Return on asset (TTM) | 0.0454 | |
| Return on equity (TTM) | -0.0736 | |
| Revenue TTM | 15,845,999,616 | |
| Revenue per share TTM | 14.1610 | |
| Quarterly Revenue Growth (YOY) | 0.1480 | |
| Quarterly Earnings Growth (YOY) | 0.4000 | |
| Gross Profit (TTM) | 6,973,000,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 5.5897 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.9863 | |
| Revenue Enterprise Value | 2.0495 | |
| EBITDA Enterprise Value | 20.8433 | |
| Shares | ||
| Shares Outstanding | 1,132,640,000 | |
| Shares Float | 1,112,887,603 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 52.60 | |
06/25 08:00 EST - businesswire.com
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pending litigation with respect to taxes payable for the Company's taxable years 2008-2020. Under the terms of the agreement the Company will pay a total of $750 million in installments between 2024 to 2029. This allows Teva to end this historical income tax issue, and to continue to focus on its com.
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pending litigation with respect to taxes payable for the Company's taxable years 2008-2020. Under the terms of the agreement the Company will pay a total of $750 million in installments between 2024 to 2029. This allows Teva to end this historical income tax issue, and to continue to focus on its com.
06/24 11:40 EST - reuters.com
Teva launches generic version of Novo Nordisk's diabetes drug Victoza
Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.
Teva launches generic version of Novo Nordisk's diabetes drug Victoza
Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.
06/24 09:50 EST - businesswire.com
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States. “By launching an authorized generic for Victoza® (liraglutide injection 1.8mg), we are providing patients with type 2 diabetes another option for this important treatment,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Te.
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza®1 (liraglutide injection 1.8mg), in the United States. “By launching an authorized generic for Victoza® (liraglutide injection 1.8mg), we are providing patients with type 2 diabetes another option for this important treatment,” said Ernie Richardsen, SVP, Head of U.S. Commercial Generics at Te.
06/13 17:35 EST - reuters.com
Teva sues Corcept over mifepristone 'monopoly' for rare disorder
Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome.
Teva sues Corcept over mifepristone 'monopoly' for rare disorder
Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome.
06/07 10:57 EST - seekingalpha.com
Teva Pharmaceutical: Buy This Bargain Before It's Gone
Since Richard Francis became CEO in early 2023, his 'Pivot to Growth' strategy has continued to bear fruit. On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & Johnson about $2.45 billion in the first quarter of 2024. Austedo/Austedo XR sales totaled $282 million in the first three months of 2024, up 65.9% yearly, thanks to its competitive advantage in the fast-growing tardive dyskinesia therapeutics market.
Teva Pharmaceutical: Buy This Bargain Before It's Gone
Since Richard Francis became CEO in early 2023, his 'Pivot to Growth' strategy has continued to bear fruit. On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & Johnson about $2.45 billion in the first quarter of 2024. Austedo/Austedo XR sales totaled $282 million in the first three months of 2024, up 65.9% yearly, thanks to its competitive advantage in the fast-growing tardive dyskinesia therapeutics market.
06/04 16:05 EST - businesswire.com
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be av.
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be av.
06/04 13:40 EST - zacks.com
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
06/01 14:25 EST - businesswire.com
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophren.
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophren.
06/01 14:20 EST - businesswire.com
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients' quality of life. These interim findings from the IMPACT-TD study were presented at the 2024 Psych Congress Elevate Annual Meeting, taking place from May 30.
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, reinforcing that TD has a wide-reaching, multidimensional impact on patients' quality of life. These interim findings from the IMPACT-TD study were presented at the 2024 Psych Congress Elevate Annual Meeting, taking place from May 30.
05/31 07:02 EST - marketbeat.com
2 Generic Drug Makers With Growing Runways
Brand-name drug costs continue to climb, but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. Generics are loved by health insurers, Medicare, and patients as they contain the same compounds and active ingredients for a cheaper price.
2 Generic Drug Makers With Growing Runways
Brand-name drug costs continue to climb, but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. Generics are loved by health insurers, Medicare, and patients as they contain the same compounds and active ingredients for a cheaper price.
05/16 06:15 EST - investorplace.com
Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade
Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. The Biden administration is attacking businesses across the board, such as its recent assault on the oil industry.
Patent Peril: 3 Stocks at Risk From the FTC's Drug Crusade
Several drug stocks are at risk as the Federal Trade Commission is going after pharmaceutical companies that it alleges are trying to keep generic drugs at bay from their branded products. The Biden administration is attacking businesses across the board, such as its recent assault on the oil industry.
05/15 08:15 EST - businesswire.com
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership T.
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership T.
05/14 14:35 EST - seekingalpha.com
Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript)
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) BofA Securities 2024 Health Care Conference May 14, 2024 11:40 AM ET Company Participants Jason Gerberry - Managing Director, US Specialty Pharma and Smid Cap Biotech Richard Francis - President & CEO Eric Hughes - EVP, Global R&D & CMO Conference Call Participants Jason Gerberry
Teva Pharmaceutical Industries Limited (TEVA) BofA Securities 2024 Health Care Conference (Transcript)
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) BofA Securities 2024 Health Care Conference May 14, 2024 11:40 AM ET Company Participants Jason Gerberry - Managing Director, US Specialty Pharma and Smid Cap Biotech Richard Francis - President & CEO Eric Hughes - EVP, Global R&D & CMO Conference Call Participants Jason Gerberry
05/13 10:46 EST - zacks.com
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
05/10 07:08 EST - marketbeat.com
These 7 Stocks Surged Double-Digits and Have Double-Digits to Go
Earnings reports often catalyze big moves in a stock's price; the bigger the move, the more conviction the market shows. Catalysts for these moves include better-than-expected results, gained traction, and improved guidance pointing to additional upside.
These 7 Stocks Surged Double-Digits and Have Double-Digits to Go
Earnings reports often catalyze big moves in a stock's price; the bigger the move, the more conviction the market shows. Catalysts for these moves include better-than-expected results, gained traction, and improved guidance pointing to additional upside.
05/09 13:15 EST - zacks.com
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
TEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for sales. It announces promising data from a phase III study on schizophrenia candidate, olanzapine.
05/08 10:36 EST - zacks.com
Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
05/08 09:15 EST - marketwatch.com
Teva Pharmaceutical's stock climbs as schizophrenia treatment shows promise
Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA jumped more than 6% premarket Wednesday after the company reported first-quarter sales that topped expectations and released positive late-stage trial data on a schizophrenia treatment.
Teva Pharmaceutical's stock climbs as schizophrenia treatment shows promise
Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA jumped more than 6% premarket Wednesday after the company reported first-quarter sales that topped expectations and released positive late-stage trial data on a schizophrenia treatment.
05/08 08:53 EST - investors.com
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter
Teva stock surged to a five-year high Wednesday after the drugmaker kept its full-year guidance despite missing first-quarter profit views.
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter
Teva stock surged to a five-year high Wednesday after the drugmaker kept its full-year guidance despite missing first-quarter profit views.
05/08 07:20 EST - reuters.com
Teva Pharm Q1 profit falls short of estimates, revenue gains
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease rose.
Teva Pharm Q1 profit falls short of estimates, revenue gains
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease rose.